The atrial fibrillation devices market size has grown rapidly in recent years. It will grow from $8.6 billion in 2025 to $9.61 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing prevalence of atrial fibrillation, rising geriatric population, growth in cardiovascular disease burden, expansion of electrophysiology labs, adoption of implantable cardiac devices.
The atrial fibrillation devices market size is expected to see rapid growth in the next few years. It will grow to $14.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancements in ablation technologies, increasing use of remote patient monitoring, rising awareness of stroke prevention, expansion of ambulatory surgical centers, technological innovation in mapping and navigation systems. Major trends in the forecast period include rising adoption of catheter ablation procedures, growing use of wearable and remote ecg monitoring devices, increasing demand for minimally invasive afib treatments, expansion of left atrial appendage closure device usage, improved focus on early detection and long-term rhythm monitoring.
The increasing burden of cardiovascular diseases is expected to drive the growth of the atrial fibrillation device market in the coming years. Cardiovascular diseases encompass conditions that affect the heart and blood vessels, such as heart attacks, strokes, and hypertension. The growing prevalence of these conditions is largely attributed to rising global rates of obesity and diabetes, combined with sedentary lifestyles and unhealthy eating habits. Atrial fibrillation (AFib) devices are essential for managing cardiovascular diseases by detecting, monitoring, and treating irregular heart rhythms, which are frequently linked to underlying heart problems. For example, in June 2024, the American Heart Association, a US-based public health organization, reported that as the prevalence of high blood pressure is projected to increase from 51.2% to 61%, the number of individuals diagnosed with cardiovascular diseases is expected to grow from 128 million in 2020 to over 184 million by 2050. Thus, the rising incidence of cardiovascular diseases is contributing to the expansion of the atrial fibrillation device market.
Key players in the atrial fibrillation devices market are focusing on technological advancements, such as patient-centric clinical decision support tools, to improve diagnostic accuracy, customize treatment strategies, and enhance patient outcomes. These tools are digital systems designed to assist healthcare providers by analyzing individual patient data to inform more personalized care decisions. For instance, in August 2023, GE HealthCare Technologies Inc., a US-based medical technology company, introduced CardioVisio for Atrial Fibrillation, a digital clinical decision support tool created to streamline clinician workflows and support targeted care for AFib patients. The tool helps visualize AFib progression, incorporating previous diagnoses, treatments, medications, and related conditions. It also provides therapy recommendations based on established guidelines, reducing the likelihood of diagnostic errors and facilitating more efficient clinical decision-making. CardioVisio consolidates scattered patient data into an accessible format, helping medical professionals manage atrial fibrillation more effectively and efficiently.
In November 2023, Johnson & Johnson MedTech, a US-based medical technology firm, acquired Laminar Inc. for an undisclosed amount. This acquisition aims to enhance Johnson & Johnson MedTech’s position in the atrial fibrillation device sector and broaden its range of solutions focused on stroke prevention and cardiac care. Laminar Inc. is a US-based company specializing in the development of innovative devices for left atrial appendage elimination, which are used to prevent strokes in patients with atrial fibrillation.
Major companies operating in the atrial fibrillation devices market are Johnson And Johnson Services Inc, Abbott Laboratories, Medtronic Public Limited Company, Koninklijke Philips NV, Boston Scientific Corporation, Shanghai MicroPort EP MedTech Co Ltd, Japan Lifeline Co Ltd, AliveCor Inc, CardioFocus Inc, Imricor Medical Systems Inc, Kardium Inc, Stereotaxis Inc, Volta Medical, Osypka AG, CathRx Ltd, BIOTRONIK SE And Co KG, EP Solutions SA, CardiacSense Ltd, Biosense Webster Inc, Abbott Electrophysiology, Medtronic Cardiac Rhythm And Heart Failure, Boston Scientific Electrophysiology.
North America was the largest region in the atrial fibrillation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial fibrillation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atrial fibrillation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the atrial fibrillation devices market by increasing costs for imported electronic components, ablation catheters, and imaging systems used in device manufacturing. Catheter-based devices and implantable devices are most affected, particularly in regions such as Asia-Pacific and Europe that rely on cross-border supply chains. These tariffs have led to higher device prices and procurement delays for hospitals and cardiac centers. However, they have also encouraged localized manufacturing, supplier diversification, and cost-optimized device development to strengthen regional market resilience.
The atrial fibrillation devices market research report is one of a series of new reports that provides atrial fibrillation devices market statistics, including atrial fibrillation devices industry global market size, regional shares, competitors with a atrial fibrillation devices market share, detailed atrial fibrillation devices market segments, market trends and opportunities, and any further data you may need to thrive in the atrial fibrillation devices industry. This atrial fibrillation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Atrial fibrillation (AFib) devices are medical technologies developed to detect, monitor, or treat atrial fibrillation, a prevalent heart rhythm disorder characterized by irregular beating of the heart’s upper chambers. These devices include implantable cardiac monitors, pacemakers, defibrillators, catheter ablation systems, and wearable electrocardiogram (ECG) monitors. The primary objective of AFib devices is to restore normal heart rhythm, minimize stroke risk, and enhance quality of life.
The main types of atrial fibrillation devices include implantable devices, external devices, and catheter-based devices. Implantable devices refer to tools such as pacemakers, implantable cardioverter defibrillators (ICDs), and implantable loop recorders, which are surgically placed within the body to monitor, regulate, or correct heart rhythm by delivering electrical impulses or continuously recording cardiac activity. These devices are used across various applications, including electrophysiology ablation catheters, cardiac monitors or implantable loop recorders, electrophysiology diagnostic catheters, mapping and recording systems, access devices, intracardiac echocardiography, left atrial appendage closure devices, and other related tools. They operate using technologies such as radiofrequency, cryotherapy, ultrasound, and other advanced methods. Distribution channels include direct sales, distributors, and online platforms, serving end users such as hospitals, cardiac centers, ambulatory surgical centers, and other healthcare providers.
The atrial fibrillation devices market consists of revenues earned by entities providing services such as diagnostic services, therapeutic services, and patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The atrial fibrillation devices market also includes sales of cryoablation catheters, laser ablation systems, and hybrid ablation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The atrial fibrillation devices market size is expected to see rapid growth in the next few years. It will grow to $14.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancements in ablation technologies, increasing use of remote patient monitoring, rising awareness of stroke prevention, expansion of ambulatory surgical centers, technological innovation in mapping and navigation systems. Major trends in the forecast period include rising adoption of catheter ablation procedures, growing use of wearable and remote ecg monitoring devices, increasing demand for minimally invasive afib treatments, expansion of left atrial appendage closure device usage, improved focus on early detection and long-term rhythm monitoring.
The increasing burden of cardiovascular diseases is expected to drive the growth of the atrial fibrillation device market in the coming years. Cardiovascular diseases encompass conditions that affect the heart and blood vessels, such as heart attacks, strokes, and hypertension. The growing prevalence of these conditions is largely attributed to rising global rates of obesity and diabetes, combined with sedentary lifestyles and unhealthy eating habits. Atrial fibrillation (AFib) devices are essential for managing cardiovascular diseases by detecting, monitoring, and treating irregular heart rhythms, which are frequently linked to underlying heart problems. For example, in June 2024, the American Heart Association, a US-based public health organization, reported that as the prevalence of high blood pressure is projected to increase from 51.2% to 61%, the number of individuals diagnosed with cardiovascular diseases is expected to grow from 128 million in 2020 to over 184 million by 2050. Thus, the rising incidence of cardiovascular diseases is contributing to the expansion of the atrial fibrillation device market.
Key players in the atrial fibrillation devices market are focusing on technological advancements, such as patient-centric clinical decision support tools, to improve diagnostic accuracy, customize treatment strategies, and enhance patient outcomes. These tools are digital systems designed to assist healthcare providers by analyzing individual patient data to inform more personalized care decisions. For instance, in August 2023, GE HealthCare Technologies Inc., a US-based medical technology company, introduced CardioVisio for Atrial Fibrillation, a digital clinical decision support tool created to streamline clinician workflows and support targeted care for AFib patients. The tool helps visualize AFib progression, incorporating previous diagnoses, treatments, medications, and related conditions. It also provides therapy recommendations based on established guidelines, reducing the likelihood of diagnostic errors and facilitating more efficient clinical decision-making. CardioVisio consolidates scattered patient data into an accessible format, helping medical professionals manage atrial fibrillation more effectively and efficiently.
In November 2023, Johnson & Johnson MedTech, a US-based medical technology firm, acquired Laminar Inc. for an undisclosed amount. This acquisition aims to enhance Johnson & Johnson MedTech’s position in the atrial fibrillation device sector and broaden its range of solutions focused on stroke prevention and cardiac care. Laminar Inc. is a US-based company specializing in the development of innovative devices for left atrial appendage elimination, which are used to prevent strokes in patients with atrial fibrillation.
Major companies operating in the atrial fibrillation devices market are Johnson And Johnson Services Inc, Abbott Laboratories, Medtronic Public Limited Company, Koninklijke Philips NV, Boston Scientific Corporation, Shanghai MicroPort EP MedTech Co Ltd, Japan Lifeline Co Ltd, AliveCor Inc, CardioFocus Inc, Imricor Medical Systems Inc, Kardium Inc, Stereotaxis Inc, Volta Medical, Osypka AG, CathRx Ltd, BIOTRONIK SE And Co KG, EP Solutions SA, CardiacSense Ltd, Biosense Webster Inc, Abbott Electrophysiology, Medtronic Cardiac Rhythm And Heart Failure, Boston Scientific Electrophysiology.
North America was the largest region in the atrial fibrillation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial fibrillation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atrial fibrillation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the atrial fibrillation devices market by increasing costs for imported electronic components, ablation catheters, and imaging systems used in device manufacturing. Catheter-based devices and implantable devices are most affected, particularly in regions such as Asia-Pacific and Europe that rely on cross-border supply chains. These tariffs have led to higher device prices and procurement delays for hospitals and cardiac centers. However, they have also encouraged localized manufacturing, supplier diversification, and cost-optimized device development to strengthen regional market resilience.
The atrial fibrillation devices market research report is one of a series of new reports that provides atrial fibrillation devices market statistics, including atrial fibrillation devices industry global market size, regional shares, competitors with a atrial fibrillation devices market share, detailed atrial fibrillation devices market segments, market trends and opportunities, and any further data you may need to thrive in the atrial fibrillation devices industry. This atrial fibrillation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Atrial fibrillation (AFib) devices are medical technologies developed to detect, monitor, or treat atrial fibrillation, a prevalent heart rhythm disorder characterized by irregular beating of the heart’s upper chambers. These devices include implantable cardiac monitors, pacemakers, defibrillators, catheter ablation systems, and wearable electrocardiogram (ECG) monitors. The primary objective of AFib devices is to restore normal heart rhythm, minimize stroke risk, and enhance quality of life.
The main types of atrial fibrillation devices include implantable devices, external devices, and catheter-based devices. Implantable devices refer to tools such as pacemakers, implantable cardioverter defibrillators (ICDs), and implantable loop recorders, which are surgically placed within the body to monitor, regulate, or correct heart rhythm by delivering electrical impulses or continuously recording cardiac activity. These devices are used across various applications, including electrophysiology ablation catheters, cardiac monitors or implantable loop recorders, electrophysiology diagnostic catheters, mapping and recording systems, access devices, intracardiac echocardiography, left atrial appendage closure devices, and other related tools. They operate using technologies such as radiofrequency, cryotherapy, ultrasound, and other advanced methods. Distribution channels include direct sales, distributors, and online platforms, serving end users such as hospitals, cardiac centers, ambulatory surgical centers, and other healthcare providers.
The atrial fibrillation devices market consists of revenues earned by entities providing services such as diagnostic services, therapeutic services, and patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The atrial fibrillation devices market also includes sales of cryoablation catheters, laser ablation systems, and hybrid ablation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Atrial Fibrillation Devices Market Characteristics
3. Atrial Fibrillation Devices Market Supply Chain Analysis
4. Global Atrial Fibrillation Devices Market Trends and Strategies
5. Atrial Fibrillation Devices Market Analysis of End Use Industries
7. Global Atrial Fibrillation Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Atrial Fibrillation Devices Total Addressable Market (TAM) Analysis for the Market
9. Atrial Fibrillation Devices Market Segmentation
10. Atrial Fibrillation Devices Market Regional and Country Analysis
11. Asia-Pacific Atrial Fibrillation Devices Market
12. China Atrial Fibrillation Devices Market
13. India Atrial Fibrillation Devices Market
14. Japan Atrial Fibrillation Devices Market
15. Australia Atrial Fibrillation Devices Market
16. Indonesia Atrial Fibrillation Devices Market
17. South Korea Atrial Fibrillation Devices Market
18. Taiwan Atrial Fibrillation Devices Market
19. South East Asia Atrial Fibrillation Devices Market
20. Western Europe Atrial Fibrillation Devices Market
21. UK Atrial Fibrillation Devices Market
22. Germany Atrial Fibrillation Devices Market
23. France Atrial Fibrillation Devices Market
24. Italy Atrial Fibrillation Devices Market
25. Spain Atrial Fibrillation Devices Market
26. Eastern Europe Atrial Fibrillation Devices Market
27. Russia Atrial Fibrillation Devices Market
28. North America Atrial Fibrillation Devices Market
29. USA Atrial Fibrillation Devices Market
30. Canada Atrial Fibrillation Devices Market
31. South America Atrial Fibrillation Devices Market
32. Brazil Atrial Fibrillation Devices Market
33. Middle East Atrial Fibrillation Devices Market
34. Africa Atrial Fibrillation Devices Market
36. Atrial Fibrillation Devices Market Competitive Landscape and Company Profiles
37. Atrial Fibrillation Devices Market Other Major and Innovative Companies
40. Atrial Fibrillation Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Atrial Fibrillation Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses atrial fibrillation devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for atrial fibrillation devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The atrial fibrillation devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Device Type: Implantable Devices; External Devices; Catheter-Based Devices2) By Product: Electrophysiology Ablation Catheters; Cardiac Monitors Or Implantable Loop Recorder; Electrophysiology Diagnostic Catheters; Mapping And Recording Systems; Access Devices; Intracardiac Echocardiography; Left Atrial Appendage Closure Devices; Other Products
3) By Technology: Radiofrequency; Cryotherapy; Ultrasound; Other Technologies
4) By Distribution Channel: Direct Sales; Distributors; Online Sales
5) By End-Use: Hospitals; Cardiac Centers; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Implantable Devices: Implantable Cardioverter Defibrillators; Pacemakers; Insertable Cardiac Monitors2) By External Devices: External Defibrillators; Holter Monitors; Mobile Cardiac Telemetry Devices; Electrocardiogram Monitors
3) By Catheter-Based Devices: Radiofrequency Ablation Catheters; Cryoablation Catheters; Laser Ablation Catheters; Mapping and Navigation Systems; Transseptal Access Devices
Companies Mentioned: Johnson And Johnson Services Inc; Abbott Laboratories; Medtronic Public Limited Company; Koninklijke Philips NV; Boston Scientific Corporation; Shanghai MicroPort EP MedTech Co Ltd; Japan Lifeline Co Ltd; AliveCor Inc; CardioFocus Inc; Imricor Medical Systems Inc; Kardium Inc; Stereotaxis Inc; Volta Medical; Osypka AG; CathRx Ltd; BIOTRONIK SE And Co KG; EP Solutions SA; CardiacSense Ltd; Biosense Webster Inc; Abbott Electrophysiology; Medtronic Cardiac Rhythm And Heart Failure; Boston Scientific Electrophysiology
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Atrial Fibrillation Devices market report include:- Johnson And Johnson Services Inc
- Abbott Laboratories
- Medtronic Public Limited Company
- Koninklijke Philips NV
- Boston Scientific Corporation
- Shanghai MicroPort EP MedTech Co Ltd
- Japan Lifeline Co Ltd
- AliveCor Inc
- CardioFocus Inc
- Imricor Medical Systems Inc
- Kardium Inc
- Stereotaxis Inc
- Volta Medical
- Osypka AG
- CathRx Ltd
- BIOTRONIK SE And Co KG
- EP Solutions SA
- CardiacSense Ltd
- Biosense Webster Inc
- Abbott Electrophysiology
- Medtronic Cardiac Rhythm And Heart Failure
- Boston Scientific Electrophysiology
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 9.61 Billion |
| Forecasted Market Value ( USD | $ 14.77 Billion |
| Compound Annual Growth Rate | 11.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
